Introduction {#S0001}
============

Today, in the field of advanced research, nanotechnology is undergoing extensive growth.[@CIT0001] Specifically, particles smaller than 100 nm are consistently reported to exhibit diverse, therapeutic, and bio-imaging properties.[@CIT0002] Nanomaterials have become more attractive since it was established that they can be used as a target-specific carrier with some modification.[@CIT0003] Nano-sized particles have a higher surface area to volume ratio.[@CIT0004] Their nano size imparts specific properties that have been different from their bulk.[@CIT0005],[@CIT0006] Recently, some of the metallic nanomaterials including gold, copper, aluminum, titanium, silver, and zinc oxide (ZnO) have been used in textiles as embedding agents.[@CIT0007]

ZnO nanoparticles (NPs) have been investigated thoroughly due to their distinctive features. They have good stability and are capable of being used as a diagnostic tool in cancer diagnosis and therapy.[@CIT0008] Globally, a lot of research is underway to explore their potential candidacy as drug delivery tool and behavior toward biological systems.[@CIT0009]--[@CIT0014]

Topical applications with ZnO as active moiety have been reported for their various antibacterial, anti-inflammatory, and astringent properties.[@CIT0015]--[@CIT0017] These wide-spread application trends gave rise to safety concerns about ZnO NPs, and toxicity studies have been carried out in response. In vivo testing has been carried out in animals at doses ranging from 250--2,000 mg/kg body weight. Chronic exposure at 250 mg/kg affected body weight and serum glutamic-pyruvic transaminase activity.[@CIT0018] ZnO NPs at oral doses of 300 and 2,000 mg/kg (short-term exposure) in Swiss mice resulted in reduced sperm count, aberrant morphology, and genotoxicity in a dose-dependent manner,[@CIT0019] while in basal diet they caused developmental toxicity at 5,000 mg/kg.[@CIT0020]

Generally, shape and size are considered determinant factors in the toxicity of ZnO NPs,[@CIT0021] while their composition affects stability and biocompatibility.[@CIT0022] It has already been documented that these NPs are capable of reaching various organs after oral administration.[@CIT0023] Mechanistically, ZnO NPs impart their toxic effects due to generation of Zn^2+^ ions and free radicals after dissolution.[@CIT0024] In animal studies, ZnO NPs have exhibited their toxic effects on all organs including the nervous system, GIT, lungs, cardiovascular system, genitourinary system, and blood (in mice).[@CIT0025] Shrivastava et al, in 2014, reported neurotoxic effects of ZnO NPs upon oral administration, which resulted in an upsurge of norepinephrine and dopamine in the cerebral cortex.[@CIT0026] Although zinc, in trace amounts, has a positive impact on overall central nervous system functioning,[@CIT0027] in higher concentrations, it leads to oxidative stress and chronic exposure resulting in a higher level of malondialdehyde.[@CIT0028] Chronic exposure leads to a decline in cognitive performance by enhancing, mainly, apoptosis of pyramidal neurons.[@CIT0029],[@CIT0030] Additionally, it has also been established that ZnO NPs induced synaptic plasticity by enhancing neuronal excitability in an animal model of mood disorder.[@CIT0031] Currently, researchers are trying to diminish the toxic effects of NPs through coating,[@CIT0032] simultaneously, green synthesis is another approach to combat toxic effects of the chemicals involved in production of NPs.[@CIT0033] Now, chemical methods are being replaced by eco-friendly and cost-effective green synthesis techniques[@CIT0003] providing a wide range of sizes and shapes.[@CIT0034] ZnO NPs have successfully been synthesized using various plant extracts as reducing agents.[@CIT0035] Yet, toxicities and bio-hazards of ZnO NPs are conflicting.[@CIT0036]

Chloroquine phosphate (CQ) is primarily used for treating malaria, rheumatoid arthritis, systemic lupus erythematosus, and some viral infections. One of the side effects associated with CQ use in humans is pruritus.[@CIT0037] CQ-induced pruritus is a "sharp biting" sensation which is observed after CQ administration.[@CIT0037]--[@CIT0039] As pruritus is one of the symptoms of dermatological malfunctioning,[@CIT0040] this side effect of CQ has been used to study pruritus in mice.[@CIT0037],[@CIT0038]

The current study was designed to explore the toxic effects, as well as other behavioral parameters of chemically and green synthesized ZnO NPs on CQ-induced pruritus using a murine model.

Material and methods {#S0002}
====================

Animals {#S0002-S2001}
-------

Female BALB/c mice with weight range 20--30 g were purchased from National Institute of Health, Islamabad, Pakistan. Animals were kept under controlled temperature ranging from 22ºC--25ºC, were provided with hygienic environment with saw bedding (which was changed on alternative days), and 12/12 hour light-dark cycles starting from 08:00 am to 08:00 pm. Animals were provided free access to food and water ad libitum. All the experimental protocols and animal handling procedures were carried out according to regulations guided by the UK 1986 Animals (scientific procedures) Act.[@CIT0043] Ethical approval for the work was obtained from Research Ethics Committee COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan under the certificate number PHM.Eth/CS-M01/18--002.

Chemicals {#S0002-S2002}
---------

Chemicals used were ZnO NPs (100 nm) (Sigma-Aldrich Co., St Louis, MO, USA), ZnO NPs (20--30 nm) (Alfa Aesar USA), ZnO NPs (25--30 nm, green synthesized in the lab using *Aloe vera* extract),[@CIT0044] and chloroquine phosphate ampule (322.5 mg/5 mL) (Shanxi Shuguang Pharma Pvt. Ltd, China).

Characterization of ZnO NPs {#S0002-S2003}
---------------------------

Scanning electron microscopy (SEM) was carried out to observe the surface morphology of ZnO NPs (purchased and green synthesized ZnO NPs) using JSM-IT100 scanning electron microscope. The size and crystallinity of all the samples were evaluated using X-ray powder diffraction (XRD) (JDX 3532, JEOL, Tokyo, Japan) technique at CuKa (1.5418Å) and 2 theta-range was 20--70°.

Drug administration {#S0002-S2004}
-------------------

For pruritus induction, CQ was diluted to 3.2 mg/mL with saline and administered subcutaneously (SC) at a dose of 32 mg/kg body weight. Samples of ZnO NPs were dispersed in saline. They were sonicated for 30 minutes and properly vortexed each time before use. ZnO NPs were administered orally (PO) at a dose of 250, 500, and 750 mg/kg body weight.[@CIT0018]--[@CIT0020]

Behavioral experiments {#S0002-S2005}
----------------------

Animals (according to each size and dose of ZnO NPs) were divided into eleven groups of six mice each. These were: control (normal saline), CQ-treated animals, ZnO NP-treated (250 mg/kg), ZnO NP-treated (500 mg/kg), and ZnO NP-treated (750 mg/kg). ZnO NPs were administered orally to the mice. After 1 hour of ZnO NPs\' administration, pruritus was induced using CQ (32 mg/kg) in 0.3 mL SC injection at the nape of the neck of the mouse to observe the scratching behavior.[@CIT0045] Each mouse was used once.

The mice were taken out of the cage briefly for oral gavage and injection, and returned to the same cage. The behavior was recorded using a CAT-1 video camera. In order to avoid any distraction, the camera was adjusted in an unmanned condition.[@CIT0042] The number of scratching bouts near the site of injection were then counted. Each bout was instigated by moving paw to the site of injection and ended when paw was returned back to the floor or mouth.[@CIT0037],[@CIT0041] After CQ administration the scratching bouts were counted during 30 minutes and simultaneous behavioral changes like socialization and locomotion were also monitored. The number of itching bouts the mouse experienced was revealed by how frequently the mouse scratches itself.[@CIT0045]--[@CIT0047] Locomotion was evaluated by the number of lines crossed by the mice in 30 minutes in open field locomotion box.[@CIT0048]

Results {#S0003}
=======

Characterization {#S0003-S2001}
----------------

SEM results are shown in [Figure 1A](#F0001){ref-type="fig"}--[C](#F0001){ref-type="fig"}. From the images, spherical appearance of NPs was confirmed. Standard XRD pattern for ZnO according to the Joint Committee on Powder Diffraction Standards (JCPDS) is shown in [Figure 2A](#F0002){ref-type="fig"}. The peaks for ZnO NPs (100 nm), as shown in [Figure 2B](#F0002){ref-type="fig"}, were at positions 31.85°, 34.40°, 36.50°, 47.60°, 56.65°, 63.00°, 68.05°, and 69.25° corresponding to (100), (002), (101), (102), (110), (103), (112), and (201) planes respectively. Similarly for ZnO (30 nm) (shown in [Figure 2C](#F0002){ref-type="fig"}) the peaks at 2θ =31.67°, 34.28°, 36.36°, 47.80°, 56.63°, 63.13°, 68.06°, and 69.10°, correspond to (100), (002), (101), (102), (110), (103), (112), and (201). For green synthesized ZnO NPs ([Figure 2D](#F0002){ref-type="fig"}) peaks were observed at 31.94°, 34.53°, 36.35°, 47.79°, 56.88°, 63.12°, 68.05°, and 69.10°, corresponding to (100), (002), (101), (102), (110), (103), (112), and (201). The relevance of sharp diffraction peaks for ZnO NPs indicated the purity of particles.[@CIT0049]--[@CIT0052] Diameters of the ZnO NPs were evaluated using Debye-Scherrer formula.[@CIT0053],[@CIT0054] Figure 1Characterization of ZnO NPs by SEM. (**A**) ZnO NPs (100 nm), (B) ZnO NPs (30 nm) and (**C**) ZnO NPs (G 30 nm).**Abbreviations:** ZnO NPs, Zinc oxide nanoparticles;G, Green synthesized. Figure 2XRD pattern of ZnO NPs (**A**) Standerd XRD pattern for ZnO (**B**) ZnO NPs (100 nm) (**C**) ZnO NPs (30 nm) (**D**) ZnO NPs (G 30 nm).**Abbreviations:** JCPDSG, Joint Committee on Powder Diffraction Standards; ZnO NPs, Zinc oxide nanoparticles; G, Green synthesized.

d = 0.89 λ/β cosθ

Where θ is the Bragg diffraction angle, β is full width at half maximum of the diffraction peak, 0.89 is Scherrer's constant, and λ is the wavelength of X-rays. It was indicated that the particles were in nanometer range confirming the average particle size of 100 nm, 30 nm, and 30 nm respectively (green synthesized ZnO NPs).[@CIT0054]

Scratching bouts {#S0003-S2002}
----------------

Scratching bouts were recorded in animals of all groups. In normal saline group, animals lacked itching. Onset of scratching was within 5 minutes of SC injection and lasted for almost 30 minutes. There were 133 scratching bouts recorded during 30 minutes in CQ-treated mice. When ZnO NPs were PO administered before SC injection of CQ, it was observed that the number of scratching bouts significantly reduced to 14, nine, and three as a result of ZnO NPs (100 nm) at doses of 250, 500, and 750 mg/kg body weight ([Figure 3](#F0003){ref-type="fig"}).Figure 3Scratching bouts/30 minutes with CQ and effect of ZnO NPs (100, 30 nm and G 30 nm)**Abbreviations:** N/S; normal saline, CQ, Chloroquine; ZnO NPs, Zinc oxide nanoparticles; G, Green synthesized.

 {#S0003-S2003}

There was a further reduction in number of scratching bouts to nine, nine, and eight as a result of ZnO NPs (30 nm) at respective doses of 250, 500, and 750 mg/kg body weight ([Figure 3](#F0003){ref-type="fig"}). Furthermore, the experiment was repeated at the same PO doses of ZnO NPs (green synthesized 30 nm). Observations were recorded and showed four, three, and three scratching bouts respectively for doses of 250, 500, and 750 mg/kg body weight ([Figure 3](#F0003){ref-type="fig"}).

Socialization {#S0003-S2004}
-------------

Socialization with each other was observed after administration of ZnO NPs as compared with normal saline and CQ-treated group ([Figure 4](#F0004){ref-type="fig"}). All animals showed improved socialization behavior after ZnO NPs\' administration. The effect persisted even after CQ was administered to the mice.Figure 4Socialization response of mice with CQ and effect of ZnO NPs (100, 30 nm and G 30 nm) at various oral doses.**Abbreviations:** N/S; normal saline, CQ, Chloroquine; ZnO NPs, Zinc oxide nanoparticles; G, Green synthesized.

Locomotion {#S0003-S2005}
----------

Locomotion was significantly decreased in ZnO NP (100 and 30 nm)-treated mice as compared to normal saline and CQ treated mice. Locomotion was enhanced in mice administered green synthesized ZnO NPs as compared to commercially available ZnO NPs of 100 and 30 nm sizes ([Figure 5](#F0005){ref-type="fig"}).Figure 5Comparison of Locomotion activity among CQ and ZnO NPs-treated mice at various sizes and doses.**Abbreviations:** N/S; normal saline, CQ, Chloroquine; ZnO NPs, Zinc oxide nanoparticles: G, Green synthesized.

Discussion {#S0004}
==========

Data obtained from XRD analysis were in agreement with the JCPDS PDF no 36--1451 for the standard hexagonal polycrystalline structure of ZnO.[@CIT0055] The results for green synthesized ZnO NPs were in good agreement with commercially available ZnO NPs (30 nm). When scratching behavior was evaluated for these NPs, a significant (*P*≤0.001) decrease in intensity of bouts was observed after PO administration of ZnO NPs in all doses and particle sizes (as shown in [Figure 3](#F0003){ref-type="fig"}). When the decrease in itching was recorded among different particle sizes and doses, it was observed that there was no significant difference among ZnO NPs of 100 nm and 30 nm, chemically and green synthesized.

The induction of itching by using CQ (32 mg/kg) was consistent with previous studies.[@CIT0056] CQ is known to activate Mrgpr A3 receptors (G protein-coupled receptors), that primarily contribute to scratching desire.[@CIT0041] These acute scratching bouts can be inhibited by blockers (eg, anti-depressants, nalfurafin, and N-methyl-D-aspartate receptor antagonist) of TRPA1/TRPV1.[@CIT0057] However, CQ-induced pruritus is also mediated by increased production of NO (linked to cGMP).[@CIT0041] In in vivo studies, ZnO NPs have been reported to reduce NO level.[@CIT0036],[@CIT0041] Here, the reduction in scratching intensity could be attributed to the ZnO NPs' NO lowering property. ZnO NPs are reported to induce toxicological response systemically, but in this study it was observed that CQ-induced itching was relieved by ZnO NPs.

ZnO NPs were previously reported to improve memory impairment, anxiety, and oxidative stress in mice.[@CIT0058] In this study, it was established that ZnO NPs significantly improved socialization in mice as compared to the control group. Earlier, Sultana and Najam (2012) reported that *Aloe vera* caused reduction in locomotion and sedation when independently tested PO for depression, locomotion, and anxiety in mice.[@CIT0059],[@CIT0060] ZnO NPs induced improved socialization further need neuro-endocrine profiling. In this study, administration of ZnO NPs had a calming effect in comparison to the CQ group. However, mice that were given green synthesized ZnO NPs showed significantly (*P*˂0.001) improved locomotion in comparison to 100 and 30 nm (commercially available) ZnO NPs. *Aloe vera* has already been reported to have an anti-depressive effect.[@CIT0060] The results of this study support the concept that green synthesis successfully ameliorates the harmful effects of intervening chemicals used during synthesis.[@CIT0061],[@CIT0062] Here, the effect of green synthesized NPs could have been related to the synthesis method of ZnO NPs. This aspect of green synthesis might be a contributing factor to the improved locomotion in mice observed with green synthesized ZnO NPs. More studies are warranted to explore ZnO NPs\' effect on the role of gender, as this study was conducted using female mice only.

Conclusion {#S0005}
==========

Instead of aggravating the dermatologic condition, ZnO NPs, overall, imparted a significant protective effect in a murine model of CQ-induced pruritus. Additionally, socialization was improved significantly at a lower dose (250 mg/kg) with green synthesized NPs, which showed a less depressive effect, unlike commercially available ZnO NPs. Studies using non-toxic doses of ZnO NPs are warranted to explore their effect on CQ-induced pruritus, socialization, and locomotion.
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